DBV filed a BLA for the Viaskin peanut patch in peanut-allergic children aged 4-7, citing phase 3 VITESSE data, and requested priority review.
News|Articles|February 4, 2025
FDA news in pediatrics: January 2025
Author(s)Patrick Campbell
A recap of the FDA submissions and regulatory decisions in pediatrics from January 2025.
Advertisement
Advertisement
Navigating the ever-evolving landscape of pediatric care means staying ahead of clinical developments, regulatory shifts, and therapeutic breakthroughs—each with the potential to reshape how we support children’s health. In the January 2025 FDA update from Contemporary Pediatrics, we highlight decisions that reflect both the complexity and promise of modern pediatrics, including new drug submissions, a pivotal ban on red No. 3 in food and ingested drugs, and an expanded clearance for a familiar face.
Related to this article
The FDA accepted the Anaphylm NDA resubmission as a class 2 response, setting a March 16, 2027, PDUFA date for the sublingual epinephrine film.
Maternal high egg and peanut intake in pregnancy and lactation did not lower infant IgE-mediated egg or peanut allergy at 1 year in PrEggNut.
Brian Vickery, MD, discusses a phase 1 trial evaluating the safety and tolerability of a microneedle stamp designed to deliver peanut protein through the skin.
The FDA approved insulin icodec-abae for children 10+ with T2D, based on adult ONWARDS data and a single-dose pediatric pharmacokinetic study.
Tezepelumab produced histologic remission in up to 68.9% of patients aged 12+ with EoE vs 3.5% with placebo at week 24, sustained to week 52.
Black race was the strongest predictor of T2-high inflammation in 451 children with severe asthma adjusted for social and environmental factors.
In phase 3 SHINE-2, 50% of mirikizumab induction responders aged 6 to 17 with moderate to severe UC were in clinical remission at week 52.
Advertisement
Advertisement